Sulindac Metabolism and Synergy with Tumor Necrosis Factor-α in a Drug-Inflammation Interaction Model of Idiosyncratic Liver Injury
Authors:
- Kevin M. BeggsKBKevin M. Beggs
- Erica M. SparkenbaughESErica M. Sparkenbaugh
- A. Daniel JonesAJA. Daniel Jones
- Husam S. YounisHYHusam S. Younis
- Robert A. RothRRRobert A. Roth
- Patricia E. GaneyPGPatricia E. Ganey
- 1 October 2009
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 331 (1) , 114-121
Abstract
Sulindac (SLD) is a nonsteroidal anti-inflammatory drug (NSAID) that has been associated with a greater incidence of idiosyncratic hepatotoxicity in human patients than other NSAIDs. In previous studies, cotreatment of rats with SLD and a modestly inflammatory dose of lipopolysaccharide (LPS) led to liver injury, whereas neither SLD nor LPS alone caused liver damage. In studies presented here, further investigation of this animal model revealed that the concentration of tumor necrosis factor-α (TNF-α) in plasma was significantly increased by LPS at 1 h, and SLD enhanced this response. Etanercept, a soluble TNF-α receptor, reduced SLD/LPS-induced liver injury, suggesting a role for TNF-α. SLD metabolites in plasma and liver were determined by LC/MS/MS. Cotreatment with LPS did not increase the concentrations of SLD or its metabolites, excluding the possibility that LPS contributed to liver injury through enhanced exposure to SLD or its metabolites. The cytotoxicities of SLD and its sulfide and sulfone metabolites were compared in primary rat hepatocytes and HepG2 cells; SLD sulfide was more toxic in both types of cells than SLD or SLD sulfone. TNF-α augmented the cytotoxicity of SLD sulfide in primary hepatocytes and HepG2 cells. These results suggest that TNF-α can enhance SLD sulfide-induced hepatotoxicity, thereby contributing to liver injury in SLD/LPS-cotreated rats.Keywords
This publication has 34 references indexed in Scilit:
- Hepatotoxic Interaction of Sulindac with Lipopolysaccharide: Role of the Hemostatic SystemToxicological Sciences, 2008
- Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the ratBiochemical Pharmacology, 2004
- Hepatocellular damage from non-steroidal anti-inflammatory drugsQJM: An International Journal of Medicine, 2003
- Inflammation and Drug Idiosyncrasy—Is There a Connection?The Journal of Pharmacology and Experimental Therapeutics, 2003
- Effects of Proinflammatory Cytokines on Rat Organic Anion Transporters During Toxic Liver Injury and CholestasisHepatology, 2003
- Combination of tumor necrosis factor‐α with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude miceCancer, 2003
- Alteration of drug biotransformation and elimination during infection and inflammationPharmacology & Therapeutics, 2001
- Sulindac: Therapeutic Implications of the Prodrug/Pharmacophore EquilibriumDrug Metabolism Reviews, 1981
- Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.Drug Metabolism and Disposition, 1980
- Identification of the biologically active form of sulindac.The Journal of Pharmacology and Experimental Therapeutics, 1977